1.Quality of hepatitis B vaccine derived from human plasma produced from 1997 to 1999 in Vietnam
Journal of Preventive Medicine 2001;11(2):63-66
28 lots of HB vaccine, produced from 1997 to 1999, have been tested for sterility, safety, potency and pyrogenicity. All of the 28 lots meet the WHO's requirements for human plasma-derived hepatitis B vaccine
Hepatitis B Vaccines
;
Vaccines
2.Anti-HBs formation in only anti-HBc positive persons after one injection of hepatitis B vaccine.
Joo Yeon KIM ; Ji Yeon JANG ; Hyun Rim CHOI
Journal of the Korean Academy of Family Medicine 1993;14(11):725-733
No abstract available.
Hepatitis B Vaccines*
;
Hepatitis B*
;
Hepatitis*
;
Humans
3.Anti-HBs antibody efficacy in children after vaccination with the first generation of hepatitis B vaccine
Journal of Practical Medicine 2002;435(11):22-25
Antibody efficacy was investigated on 98 children after hepatitis B vaccination at time of 30 months after the first dose in HuÕ City. It was found that only 30.6% of children who were vaccinated in 1998 have antibody response at protectable level. 100% of those have low-level antibody response. Cause of poor antibody response can be the duration between the first and the third doses is short. 100% of children were injected vaccine at the delta muscle, instead of the lateral-anterior thigh.
Hepatitis B Vaccines
;
child
4.Assessment of immunity response capacity of B hepatitis vaccine in seaman in Hai Phong city
Journal of Practical Medicine 2004;490(10):54-59
110 seaman in Hai Phong were infected Engerise B vaccine Good immune response through antibody responsivity effect was reached. For the first injectiong, the responsivity in 72,73% of cases, GMT altained to 135,5 mIU/ml; for the 2nd and the 3 rd injections, the respective values were 81,82%, 94,55% and 327,2 mIU/ml, 680,5 mIU/ml, with p>0,05 and p< 0,001. Topic and systemic side effect rates were very low.
Hepatitis B Vaccines
;
Viral Hepatitis Vaccines
;
Male
5.Safety and immunogenicity of low-dose hepatitis B vaccine produced by National Institute of Hygiene and Epidemiology in newborns.
Journal of Preventive Medicine 2002;12(1):30-36
2 reduced doses of plasma-derived hepatitis B vaccine produced by the National Institute of Hygiene an Epidemiology (NIHE): 2.5g (VN2,5) and 5g (VN5) was compared with 2 pediatric standard doses (10g) of recombinant vaccine from 2 Korean companies. The vaccines were administrated intramuscularly in 700 neonates at months 0, 1, 2 with postvaccineation serology tested at month 8. The seroconversion rate of 2 reduced doses are comparable with 2 control groups. Geometric mean titer of low-risk newborns in group VN2,5 were similar to group VN5, but significantly lower than control groups.
Hepatitis B
;
Infant, Newborn
;
Hepatitis B Vaccines
6.Immunological response of children under one year old in Nha Trang after vaccination with hepatitis B vaccine produced by NIHE, Ha Noi
Journal of Preventive Medicine 1999;9(1):26-30
A study on immunogenicity of hepatitis B vaccine produced by NIHE, Hanoi was conducted on 240 children under 1 year old in Nha Trang during 1994-1996. The vaccination schedule was 0, 1, 6 month. Blood sampling was performed at 3, 7, 12 month after vaccination. All children were given 10g/dose. The immunogenicity was following: seroconvertion rates were 82.89%, 96.97% and 97.97% with GMT: 120.69, 473.38 and 258.2 UI/L, respectively. The antibody response rates were the same in 2 groups, but GMT of newborn was higher than on children of 6-12 months old and there was a statistical significant difference.
Immunization
;
hepatitis B vaccines
;
child
8.HLA-DQA1, HLA-DQB1 & HLA-DRB1 Alleles Distribution in Hepatitis B Vaccine Non-responder.
Il Tae KIM ; Yun Jung CHO ; Young Tae KIM
Korean Journal of Immunology 2000;22(2):81-86
No abstract available.
Alleles*
;
Hepatitis B Vaccines*
;
Hepatitis B*
;
Hepatitis*
;
HLA-DRB1 Chains*
9.The relationship between Dose of Hepatitis B Vaccine and Seroconversion Rate in Infants.
Jung Hye CHOI ; Ki Sup CHUNG ; Dong Gwan HAN
Journal of the Korean Pediatric Society 1986;29(10):32-38
No abstract available.
Hepatitis B Vaccines*
;
Hepatitis B*
;
Hepatitis*
;
Humans
;
Infant*
10.Immunogenicity and reactogenicity of a yeast recombinant DNA hepatitis B vaccine in healthy subjects.
Kyo Myong KIM ; Sang Eun CHU ; Hae Ran LEE ; Hae Sun YOON ; Kyu Man LEE ; Chang Hong MIN
Journal of the Korean Society for Microbiology 1991;26(6):493-498
No abstract available.
DNA, Recombinant*
;
Hepatitis B Vaccines*
;
Hepatitis B*
;
Hepatitis*
;
Yeasts*